Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
45,100
+4,350 (10.67%)
Sep 19, 2025, 3:30 PM KST
10.67%
Market Cap498.98B
Revenue (ttm)29.43B
Net Income (ttm)4.57B
Shares Out11.06M
EPS (ttm)444.29
PE Ratio101.51
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,834,128
Average Volume1,493,764
Open40,800
Previous Close40,750
Day's Range40,600 - 46,250
52-Week Range12,550 - 47,550
Betan/a
RSI75.94
Earnings DateAug 8, 2025

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.